Hester Biosciences Limited (BOM:524669)
2,450.55
+13.95 (0.57%)
At close: Aug 6, 2026
Hester Biosciences Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 20,846 | 10,741 | 10,667 | 11,818 | 12,934 | 23,099 | |
Market Cap Growth | 20.98% | 0.70% | -9.74% | -8.63% | -44.00% | 41.66% |
Enterprise Value | 22,805 | 12,929 | 13,063 | 14,503 | 15,490 | 24,167 |
Last Close Price | 2450.55 | 1257.16 | 1244.14 | 1375.11 | 1498.02 | 2663.40 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 15.51 | 19.31 | 38.81 | 62.57 | 48.58 | 58.75 |
Forward PE | - | 39.50 | 39.50 | 39.50 | 32.93 | 53.45 |
PS Ratio | 6.37 | 3.22 | 3.41 | 3.80 | 4.65 | 9.37 |
PB Ratio | 5.67 | 2.92 | 3.27 | 3.90 | 4.48 | 8.64 |
P/TBV Ratio | 5.95 | 3.06 | 3.47 | 4.11 | 4.67 | 8.96 |
P/FCF Ratio | 45.01 | 23.19 | 24.29 | 49.69 | - | - |
P/OCF Ratio | 32.50 | 16.75 | 16.54 | 24.53 | 54.82 | 265.14 |
PEG Ratio | - | 3.05 | 3.05 | 3.05 | 3.05 | 3.11 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 6.97 | 3.87 | 4.18 | 4.66 | 5.57 | 9.80 |
EV/EBITDA Ratio | 24.55 | 15.83 | 23.22 | 24.17 | 24.81 | 33.90 |
EV/EBIT Ratio | 30.92 | 18.66 | 28.63 | 33.63 | 36.86 | 43.91 |
EV/FCF Ratio | 49.24 | 27.92 | 29.74 | 60.97 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.53 | 0.53 | 0.65 | 0.85 | 0.95 | 0.85 |
Debt / EBITDA Ratio | 2.28 | 2.21 | 3.43 | 4.28 | 4.38 | 3.19 |
Debt / FCF Ratio | - | 4.21 | 4.86 | 10.84 | - | - |
Net Debt / Equity Ratio | 0.51 | 0.51 | 0.63 | 0.80 | 0.90 | 0.76 |
Net Debt / EBITDA Ratio | 2.38 | 2.31 | 3.66 | 4.04 | 4.16 | 2.85 |
Net Debt / FCF Ratio | - | 4.07 | 4.69 | 10.19 | -4.79 | -2.33 |
Asset Turnover | - | 0.50 | 0.48 | 0.47 | 0.45 | 0.51 |
Inventory Turnover | - | 1.23 | 1.27 | 1.24 | 1.03 | 0.99 |
Quick Ratio | - | 0.72 | 0.70 | 0.95 | 0.68 | 0.85 |
Current Ratio | - | 1.37 | 1.56 | 2.04 | 1.53 | 2.01 |
Return on Equity (ROE) | - | 16.55% | 9.16% | 7.16% | 10.09% | 15.69% |
Return on Assets (ROA) | - | 6.51% | 4.33% | 4.05% | 4.26% | 7.07% |
Return on Invested Capital (ROIC) | 10.39% | 9.65% | 6.17% | 5.23% | 5.76% | 10.22% |
Return on Capital Employed (ROCE) | - | 13.20% | 8.60% | 7.70% | 8.10% | 11.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 6.53% | 5.18% | 2.58% | 1.60% | 2.06% | 1.70% |
FCF Yield | 2.22% | 4.31% | 4.12% | 2.01% | -4.19% | -3.77% |
Dividend Yield | 0.45% | 0.88% | 0.56% | 0.44% | 0.53% | 0.38% |
Payout Ratio | - | 10.83% | 18.80% | 36.28% | 31.95% | 21.63% |
Total Shareholder Return | 1.73% | 0.88% | 0.56% | 0.44% | 0.53% | 0.38% |